S&P 500 7,623.68 −0.52%
Nasdaq 25,955.34 −0.21%
S&P/TSX 35,788.18 −0.52%
Apple 347.73 −0.14%
Nvidia 210.96 −0.59%
Microsoft 524.51 +0.66%
Shopify 236.24 −0.07%
Royal Bank 281.77 −0.36%
CAD/USD 0.7135 −0.09%
PRE-MKT · 08:40 ET
Market ClerkRecap
Mon Oct 26 · pre-market1 signal today94 insider buys this week · $48.3MCIRO short report next: Oct 31The week ahead

CTMX

CytomX Therapeutics, Inc.
NASDAQ · HEALTH CARE · PHARMACEUTICAL PREPARATIONS
2.32
−0.12 −4.92%
USD · close Oct 23
WatchTime Machine

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

Work order
58
WATCH · shorts 58
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $505.5MP/E —DIV YIELD —FCF YIELD -16.32%REV TTM $18.3M −87.0%NET INCOME −$79.7M −266.0%NET CASH $14.2M52W 2.23 – 6.75SEC XBRL · TTM TO Invalid Date

How CTMX rewrote its risk factors

10-K ITEM 1A · FY2024 → FY2025
Text kept
61%
of sentences unchanged
Added
437
new sentences
Dropped
341
sentences removed
Length
+3,454
words, now 59,952

New in FY2025

  • These risks and uncertainties include, but are not limited to, the following: • We are a clinical-stage biopharmaceutical company with a limited operating history and have not generated any revenue from product sales. • We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all. • Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. • Our product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. • Interim, “top-line,” initial and preliminary data from our clinical trials, including the ongoing Phase 1 clinical trials of varsetatug masetecan (Varseta-M) and CX-801, that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. • Our product candidates, including Varseta-M and CX-801, may cause undesirable side effects at any time during or after the clinical trial process that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including withdrawal from the market. • If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. • We will continue to conduct clinical trials and contract with third-party manufacturers in foreign countries, including Europe and China, which could expose us to risks that could have a material adverse effect on the success of our business. • Because we have no long-term contracts with and rely on third-party manufacturing and supply partners, most of which are sole source suppliers, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality. • We, or third-party manufacturers, may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any. • Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products. • The market may not be receptive to our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates. • We have entered, and may in the future seek to enter, into collaborations with third parties for the development and commercialization of our product candidates using our PROBODY platform.
  • If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our PROBODY platform and resulting product candidates. • If our collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements. • If we do not achieve our projected development and commercialization goals in the time frames we announce and expect, the commercialization of any of our product candidates may be delayed, or never attained, and our business will be harmed. • We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management. • If we are unable to successfully develop companion diagnostic tests for certain of our product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates. • We rely on third parties to conduct all of our clinical trials and certain of our preclinical studies and intend to continue to do so, and if such third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects. • We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms.
  • Business Overview We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology.
  • CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform.
  • This versatile, multi-modality platform is built on a strong foundation of tumor biology expertise, including deep knowledge of tumor-associated enzymes known as proteases.
  • Our masking strategy is designed to reduce binding of biologic therapeutics to their targets until the mask is removed by proteases in the tumor microenvironment, providing more selective targeting of the tumor and optimizing the predicted therapeutic index of our clinical candidates.
  • CytomX’s experience and leadership with the PROBODY platform for over 15 years has led to a highly focused strategy for the application of its technology in product development that has resulted in a current pipeline of novel clinical-stage and pre-clinical stage programs.
  • In identifying and designing potential PROBODY therapeutics, we evaluate the following: • Target: Drug targets that have been validated previously as having clinical anti-tumor activity, but have been limited in their utility due to expression and toxicity in healthy tissues. • Indication: The significance of the clinical unmet need that may be addressed if the target could be targeted systemically and unlocked through masking. • Effector Mechanism: the PROBODY platform is highly versatile and is being applied to a wide range of modalities including antibody drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and cytokines.
  • In PROBODY therapeutic design, the goal is to align the selected indication with the most validated drug modality (e.g.
  • ADC, TCE) and cancer cell killing mechanism (e.g. cytotoxic payload) to maximize the potential for clinical activity.
  • CytomX’s two current clinical programs, varsetatug masetecan (“Varseta-M”) and CX-801 are in Phase 1 clinical development and are examples of our focused program development strategy.
  • We aim to continue to advance our clinical pipeline towards later stage development and ultimately build a commercial enterprise to maximize our impact on the treatment of cancer.
  • Varsetatug Masetecan (Varseta-M) Our most advanced clinical-stage program is Varseta-M, an investigational, conditionally activated antibody-drug conjugate (“ADC”) targeting epithelial cell adhesion molecule (“EpCAM”).
  • Varseta-M is initially focused on the lead indication of colorectal cancer (“CRC”).
  • Varseta-M is designed to bring the promise of ADCs, which have made a meaningful clinical difference in other solid tumors such as lung and breast cancer, to CRC by leveraging EpCAM as a potentially ideal CRC antigen to target this disease.
  • Varseta-M is a high affinity EpCAM antibody that is designed to preferentially bind EpCAM in the tumor microenvironment and minimize toxicities in healthy tissues, which have limited prior attempts in the field to target EpCAM systemically.
  • Varseta-M is armed with a topoisomerase-1 inhibitor payload.
  • Topoisomerase-1 inhibitors are known to have clinical activity in CRC, including irinotecan chemotherapy which is a standard component of the approved standard of care in CRC.
  • EpCAM is a high potential oncology target based on its documented high expression in many solid tumors, including CRC where it was first discovered due to its very high and uniform expression.
  • Historically, previous efforts across the drug development landscape to target this antigen systemically have been limited by dose-limiting toxicities.
  • For example, high affinity EpCAM antibodies were limited by pancreatitis and liver toxicities and discontinued.
  • However, EpCAM has been validated as a cancer target, including by the drug KORJUNY ® , which is approved for the treatment of malignant ascites in Europe.
  • KORJUNY ® , however, must be given directly into the peritoneum due to systemic toxicity, but its approval provides evidence that local delivery of an EpCAM therapeutic to the tumor can be effective.
  • The Varseta-M payload is a topoisomerase-1 inhibitor licensed from AbbVie (formerly ImmunoGen), tailored to have anti-tumor activity against EpCAM-expressing cancer types.
  • The payload-antibody linker is specifically designed to drive bystander killing of neighboring tumor cells, contributing to robust anti-tumor activity.
  • Overall, the design of Varseta-M seeks to establish a clinically meaningful therapeutic window for the systemic treatment of patients with EpCAM-expressing cancers, for the first time.
  • Varseta-M is designed to potentially address a broad range of EpCAM-expressing tumors, but is initially focused in CRC which is one of the largest unmet needs in oncology with over 1.9 million cases diagnosed annually around the world.
  • It is also a disease that is expected to grow and estimated that there will be over 3 million cases globally by 2040.
  • CRC is the second leading cause of cancer death worldwide and has a 5 year survival rate in the metastastic setting of only 13%.
  • CRC is also the leading cause of cancer death in the U.S. for patients under the age of 50 and has been growing in incidence in younger patients over the last 3 decades.
  • Varseta-M clinical development is initially being focused on late-line metastatic CRC where there is significant unmet need and treatment options are highly inadequate.
  • In third line or later metastatic CRC, patients have typically progressed through multiple chemotherapy-based regimens.
  • Later stage treatment is limited to therapies that provide single digit percentage response rates, median progression free survival of 2 to 5.6 months and overall survival outcomes ranging from approximately 6 to 11 months.
  • It is estimated that there are more than 35,000 patients in the U.S. with 3 rd line or later metastatic CRC, with the number expected to grow over the next decade.
  • While Varseta-M is initially being developed in late-line metastatic CRC, the program was developed with the vision to help a broad population of metastatic CRC patients, including those in the first- and second-line settings.
  • Given Varseta-M’s mechanism of action, our longer-term development vision is to make Varseta-M a core component of the CRC treatment landscape in earlier lines of therapy, consistent with the development strategy that has been employed for other solid tumor ADCs.
  • We plan to pursue combination strategies to progress this vision to move Varseta-M to earlier lines of therapy starting in 2026.
  • Additionally, given the broad solid tumor expression profile of EpCAM, Varseta-M has the potential to be an innovative new treatment option in a wide range of solid tumors.
  • High expression of EpCAM has been documented in other tumors such as gastric, gastroesophageal, pancreatic, ovarian, endometrial, non-small cell lung and triple negative breast cancers.
  • We plan to potentially initiate development in indications outside of CRC in the second half of 2026, with the ultimate vision to develop Varseta-M as a pan-tumor therapy.

and 397 more.

Gone since FY2024

  • These risks and uncertainties include, but are not limited to, the following: • We are a clinical-stage biopharmaceutical company with a limited operating history and have not generated any revenue from product sales. • We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all. • Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. • Our product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. • Interim, “top-line,” initial and preliminary data from our clinical trials, including the ongoing Phase 1 clinical trials of CX-2051, CX-904 and CX-801, that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. • Our product candidates may cause undesirable side effects at any time during or after the clinical trial process that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including withdrawal from the market. • If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. • We will continue to conduct clinical trials and contract with third-party manufacturers in foreign countries, including China, which could expose us to risks that could have a material adverse effect on the success of our business. • Because we have no long-term contracts with and rely on third-party manufacturing and supply partners, most of which are sole source suppliers, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality. • We, or third-party manufacturers, may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any. • We rely on third parties to conduct all of our clinical trials and certain of our preclinical studies and intend to continue to do so, and if such third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects. • Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products. • The market may not be receptive to our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates. • We have entered, and may in the future seek to enter, into collaborations with third parties for the development and commercialization of our product candidates using our PROBODY platform.
  • If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our PROBODY platform and resulting product candidates. • If our collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements. • If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect the commercialization of any of our product candidates may be delayed, or never attained, and our business will be harmed. • We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management. • If we are unable to successfully develop companion diagnostic tests for certain of our product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates. • We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms.
  • Business Overview We are a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment.
  • We aim to build a commercial enterprise to maximize our impact on the treatment of cancer.
  • By pioneering a novel class of localized biologic drug candidates, powered by our PROBODY ® therapeutic technology platform, we lead the field of masked, conditionally activated oncology therapeutics and have established biologics localization as a strategic area of research and development.
  • Our vision is to transform lives with safer, more effective therapies with the goal of addressing major unmet needs in oncology.
  • Our proprietary, versatile, multi-modality PROBODY technology platform is designed to enable conditional activation of biologic therapeutic candidates within the tumor microenvironment while minimizing drug activity in healthy tissues and circulation.
  • Our platform is built on a strong foundation of tumor biology expertise including deep knowledge of tumor-associated enzymes known as proteases.
  • Proteases are tightly controlled in normal tissues but often dysregulated and active in the tumor microenvironments where they play important roles in cancer cell migration, invasion and metastasis.
  • Leveraging our deep scientific knowledge, we conceived of and constructed our PROBODY therapeutic platform which allows us to genetically engineer biologic therapeutic candidates to contain protease-cleavable masks.
  • Our masking strategy is designed to reduce binding of biologic drugs to their targets until the mask is removed by proteases in the tumor microenvironment, providing more selective targeting of the tumor.
  • We are employing our PROBODY therapeutic platform technology to address some of the biggest challenges in oncology biologics research and development.
  • These include the validation of potential new targets for antibody-drug conjugates (“ADCs”), opening therapeutic window for novel T-cell engagers (“TCEs”) targeting solid tumors, and increasing the therapeutic index for immune modulators such as cytokines.
  • We have utilized our PROBODY therapeutic platform to build a promising clinical-stage pipeline of potential first-in-class and best-in-class clinical-stage molecules.
  • CX-2051 is an investigational, conditionally activated ADC targeting epithelial cell adhesion molecule (“EpCAM”) and is CytomX’s lead program currently in Phase 1 focused in advanced metastatic colorectal cancer (CRC).
  • CX-801 is an investigational, masked version of interferon alpha-2b (“IFNα2b”) in Phase 1 initially focused in advanced melanoma.
  • CX-904, a conditionally activated, PROBODY ® TCE, targeting the epidermal growth factor receptor (“EGFR”) on tumor cells and the CD3 receptor on T cells, was being developed by CytomX in Phase 1 dose escalation as part of a global co-development alliance with Amgen.
  • Our current clinical-stage molecules address targets or mechanisms that have been previously validated as having anti-cancer activity but that have been limited in their utilization due to systemic toxicities.
  • We have incorporated our broad masking and conditional activation expertise, and ongoing clinical trial learnings, to optimize predicted therapeutic index and the clinical potential of these promising agents through tumor localization.
  • We also have a pre-clinical pipeline, including multiple collaboration programs.
  • CytomX has established and has ongoing research collaborations with partners Amgen, Astellas, Bristol Myers Squibb, Moderna, and Regeneron with the majority of these programs currently focused on TCEs.
  • Our Corporate Strategy We are utilizing our proprietary, versatile, multi-modality PROBODY platform to create a pipeline of biologic therapeutics to improve the lives of people with cancer and to build a long-term, multi-product, commercial biopharmaceutical company.
  • We aim to achieve this goal by: • Advancing potentially first-in-class therapies against validated, high potential anti-cancer targets that have not yet been broadly developed as systemic therapies because of target expression in healthy tissue.
  • CX-2051, targeting EpCAM, is a novel ADC program in this category.
  • CX-2051 is designed to optimize the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer (CRC).
  • CX-2051 is armed with a cytotoxic payload (CAMP59), a camptothecin-based topoisomerase-1 inhibitor, a drug class with long history in the treatment of many cancers.
  • The investigational new drug application (“IND”) for CX-2051 was allowed to proceed by the FDA in January of 2024 and a Phase 1 study was initiated in the second quarter of 2024.
  • CX-2051 is currently in Phase 1 dose escalation.
  • In Phase 1 dose escalation to date, CX-2051 has demonstrated a favorable tolerability profile.
  • Doses predicted to be therapeutically active have been attained.
  • The CX-2051 Phase 1 study is ongoing and has reached the seventh dose level.
  • Initial CX-2051 data in advanced metastatic CRC is expected in the first half of 2025. • Unlocking high potential immunotherapeutics that have been previously limited in their systemic use due to toxicities.
  • To this end, we have advanced CX-801, a masked version of interferon alpha-2b, towards the clinic.
  • Despite this previous validation, IFNα2b-based systemic therapies have been limited in their utilization due to systemic toxicities.
  • The IND for CX-801 was allowed to proceed by the FDA in January of 2024 and commenced Phase 1 clinical testing in the third quarter of 2024.
  • The Phase 1 study is focused in advanced melanoma and will investigate CX-801 as monotherapy and in combination with PD-1 inhibitor, KEYTRUDA ® .
  • The Phase 1 study is currently in the fourth monotherapy dose escalation cohort where the dose of CX-801 exceeds the approved dose of the unmasked peginterferon alfa-2b (SYLATRON™).
  • Initial Phase 1a translational data in advanced melanoma is expected in the second half of 2025. • Leveraging the multi-modality capabilities of our platform to advance novel, high potential therapeutic formats into the clinic such as TCEs.
  • The field of TCEs for solid tumors has gained momentum as a strategic area of research and development but continues to be challenging for many targets due to limited therapeutic window.
  • We believe our PROBODY platform is well-suited to address this challenge by localizing the potent anti-tumor activity of TCEs and potentially limiting systemic toxicities.

and 301 more.

Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2024 ↗, FY2025 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.

Watch CTMX. Know when insiders buy.
One email the day a filing lands. Free.